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Summary
Objective: To assess the impact of weight reduction on serum adipocytokines, C-reactive protein (CRP), and insulin 
sensitivity in hypertensive female patients with central obesity.
Methods: This study was performed using the database and stored serum samples of female patients who had participated 
in an intervention study focused on weight loss. Thirty hypertensive women aged 18 to 65, body mass index (BMI) ≥ 27 
kg/m², and central obesity were selected. They were randomly assigned to receive either a low-calorie diet plus orlistat 
120 mg three times daily or a low-calorie diet alone for 16 weeks. Patients who experienced weight loss greater than 
5% (n = 24) were assessed for blood pressure, anthropometric parameters, visceral fat, insulin resistance (HOMA-R 
- homeostasis model assessment of insulin resistance) and sensitivity (ISI - Insulin Sensitivity Index) indices, plus serum 
lipids, adipocytokines (adiponectin, leptin, IL-6, and TNF-a) and CRP levels.
Results: After BMI had been reduced by approximately 5% in both groups, visceral fat, fasting glucose, triglycerides, and 
TNF-a decreased. Only the orlistat group, which was more insulin resistant at baseline, showed a significant reduction 
in blood glucose after oral glucose load, in addition to increased insulin sensitivity.
Conclusion: This study’s findings indicate that a weight loss greater than 5% is associated with improved inflammatory 
status and decreased insulin resistance, regardless of changes in adiponectin and TNF-a levels. The greatest improvements 
in insulin sensitivity experienced by the orlistat-treated patients could not be attributed to the use of this drug because 
of the higher number of insulin-resistant subjects in this group. (Arq Bras Cardiol 2007;89(6):371-375)
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Introduction
Recently, a body of evidence has emerged indicating that 
obesity is associated with a subclinical inflammatory process. 
It is now recognized that adipose tissue expresses and secretes 
a variety of bioactive peptides, known as adipocytokines, 
which act both in loco (autocrine or paracrine activity) and 
systemically (endocrine activity), and that many of these 
substances are involved in inflammatory phenomena1. 
It is important that obesity be viewed as an inflammatory 
state, because inflammation may be one of the links 
among obesity and insulin resistance, hypertension, and 
cardiovascular disease. Tumor necrosis factor-alpha (TNF-
a) and interleukin 6 (IL-6) are among the most studied 
proinflammatory adipocytokines, both of which are associated 
with insulin resistance and hypertension2.  Adiponectin is 
another important adipocytokine, associated with insulin 
sensitivity and anti-inflammatory action, with the distinguishing 
characteristic of being inversely correlated with obesity2. 
A number of studies have shown that weight loss is associated 
with a decline in insulin resistance and inflammatory markers3. 
Orlistat is an anti-obesity agent that can reduce dietary fat 
absorption up to 30% by inhibiting gastrointestinal lipases4,5. In 
patients with impaired glucose tolerance, orlistat was effective 
in preventing type-2 diabetes mellitus6, although it has not 
been demonstrated whether this benefit was associated with 
other advantages besides weight loss, such as better profile 
of adipocytokines or inflammatory markers.
This study sought to assess the impact of weight reduction 
on adipocytokine levels and inflammatory state in hypertensive 
female patients with central obesity. 
Methods
This study was performed using the database and stored 
serum samples of female patients who had participated 
in an intervention study focused on weight loss. Patients 
were recruited from the obesity/diabetes and hypertension 
outpatient clinic of the Departments of Endocrinology and 
Nephrology of the Federal University of São Paulo (UNIFESP). 
The study protocol was approved by the Research Ethics 
Committee of UNIFESP, and all participants signed an informed 
consent form.
At first, thirty women were selected based on the 
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- Adipocytokines and CRP: adiponectin was measured 
using the ELISA kit from B-Bridge International Inc. 
(Sunnyvale, CA, EUA).  TNF-a was measured using the ELISA 
kit from BD PharMingen (San Diego, CA, EUA), with a lower 
detection limit of 7.7 pg/ml.  Leptin was measured using 
the ELISA kit from LINCO Research (St. Charles, Missouri, 
EUA). IL-6 was measured by chemiluminescence using the 
IMMULITE-DPC kit (Los Angeles, USA), and values lower 
than 2.0 pg/mL were corrected according to the IMMULITE 
manual. CRP levels were measured by chemiluminescence 
using the IMMULITE-DPC kit (Los Angeles, EUA). The 
intra- and interassay coefficients of variation (CV) were, 
respectively, 5.7% and 7.3% for adiponectin, 6.2% and 7.5% 
for IL-6, 4.6% and 6.2% for leptin, 4.2% and 6.8% for TNF-
a, and 6.4% and 10% for CRP. 
Statistical analysis - Student’s t-test for dependent means 
was used for intragroup comparison between baseline and 
final values of quantitative variables, and the chi-squared 
test, for qualitative variables.  Student’s t-test for independent 
means was used for intergroup comparison. Correlations were 
tested by Pearson’s correlation coefficient. Data are presented 
as mean and standard deviation, and the significance level 
was set at p < 0.05.  Statistical analyses were performed using 
SPSS for Windows, version 11.5.
Results
Patient data, pre- and post-weight loss, are shown in 
Tables 1 and 2.  It can be noted that, at baseline, patients in 
the orlistat group had higher blood pressure, both systolic 
and diastolic. All patients were taking antihypertensive 
medication, with no difference in drug class between 
groups (data not shown). The orlistat group was more 
insulin-resistant, as evidenced by higher HOMA-R values 
and increased baseline glucose levels (fasting and 120 min 
post-glucose load).  There were no significant differences 
in adipocytokines and CRP levels between both groups at 
study entry (Table 2).
Both treatment groups experienced similar weight 
reduction, with a decrease in waist circumference, visceral 
fat, fasting glucose, and triglycerides. Only in the orlistat 
group did blood glucose levels show a significant decrease 
at 120 minutes after the glucose load, in addition to an 
increase in the ISI. Total cholesterol and LDL-cholesterol 
also decreased in the orlistat-treated group, but not in the 
diet-treated group.
TNF-a levels decreased in both groups (Figure 1), but IL-6 
levels remained unchanged. Although leptin levels declined in 
both groups, only in the orlistat group did this difference reach 
statistic significance.  No significant changes were found in 
adiponectin concentrations in both groups. The orlistat group 
also showed a tendency toward decreased CRP levels, though 
marginally significant in a statistical sense (p = 0.08). Taking all 
patients into account, an inverse correlation was found between 
CRP and ISI (r = -0.44; p = 0.04) (Figure 2). Changes in CRP after 
weight loss were correlated with changes in waist circumference 
(r = 0.41; p = 0.05), but not with changes in BMI.
Discussion
following inclusion criteria: age between 18 and 65; body 
mass index (BMI) > 27 kg/m²; central adiposity (waist-to-
hip ratio > 0.85 or waist circumference > 80 cm); and 
hypertension (blood pressure > 140/90 mm Hg or use of 
antihypertensive medication). Patients with known diabetes 
or those on treatment for diabetes mellitus, uncontrolled 
hypertension (diastolic blood pressure  ≥ 110 mmHg), active 
gastrointestinal disease, and a history of myocardial infarction 
or gastrointestinal surgery (for weight loss) were excluded from 
the study, as were those who had participated in any previous 
clinical trial of orlistat.  
The study sample was randomized into two groups: low-
calorie diet + orlistat or low-calorie diet alone. Patients received 
an individualized diet plan and systematic follow-up. Of the 
initial 30 patients, three dropped out before completing the 
study and three were not included in the data analysis because 
their decrease in BMI was less than 5% (two patients in the 
orlistat group and one patient in the diet group). Twenty-four 
patients were evaluated, 14 in the orlistat group and ten in the 
diet group. The orlistat group received 120 mg p.o three times 
daily taken with each of the three main meals (breakfast, lunch, 
and dinner). The study consisted of a 16-week treatment period, 
preceded by two weeks during which all patients underwent the 
initial interview, history taking, physical examination, additional 
tests, and diet prescription, with follow-up visits every fifteen 
days.  A low-energy diet was prescribed based on resting energy 
expenditure (REE), as measured by indirect calorimetry. The 
dietary intake of macronutrients was as follows: 25% lipids, 
55% carbohydrates, and 20% proteins.
All patients underwent the following measurements at 
baseline and study conclusion:
- Anthropometry: body weight, height, BMI, plus waist and 
hip circumferences.
- Body composition, measured by bioelectrical impedance 
analysis using a Quantum-BIA 101Q apparatus (Akern RJL 
Systems, Clinton Township, MI, EUA). 
- Abdominal visceral fat assessed by ultrasonography: 
defined as the distance between the internal surface of the 
rectus abdominis muscle and the anterior wall of the aorta, 
using an HTL/HDI 3000 device7. 
 - Blood pressure: both office BP and 24-hour ambulatory 
blood pressure monitoring (ABPM) were performed using an 
indirect, automated, noninvasive monitor, which transmits 
data to the SpaceLabs ABP Model 90207 analysis system 
(Data Interface Unit). 
- Biochemical analyses: oral glucose tolerance test (OGTT) 
with insulin levels determined at 0 and 120 minutes and 
insulin resistance assessed by the resistance (HOMA-R 
– homeostasis model assessment of insulin resistance)8 and 
sensitivity (ISI – Insulin Sensitivity Index) indices.  The ISI 
reflects both hepatic and peripheral sensitivity to insulin, since 
it incorporates glucose and insulin values, both fasting and at 
120-min of OGTT9. This is a relative index, in which patients 
with normal insulin sensitivity have ISI close to 1. Serum insulin 
was measured by radioimmunoassay (LINCO Research, Inc.). 
Serum total cholesterol, cholesterol fractions, and triglycerides 
were measured by enzymatic colorimetric method using an 
automated spectrophotometer (Abbott VP). 
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Our results show that an 8% decrease in BMI was associated 
with a decrease in parameters such as visceral fat, fasting 
glucose, triglycerides, and TNF-a. However, this amount of 
weight loss elicited different responses in the groups studied 
regarding glucose levels 120 minutes following oral glucose 
load and insulin sensitivity index. Although both groups were 
randomly selected, the orlistat-treated group was more insulin 
resistant and had higher fasting and post-load glucose levels. 
Therefore, the benefits found in this group may have resulted 
from the greater impact of weight loss in subjects with higher 
degree of insulin resistance, rather than being an effect of 
orlistat. The results of this study are in keeping with those 
of other studies comparing similar amounts of weight loss 
between groups with different degrees of insulin resistance 
at baseline, which have also shown significant improvement 
in insulin sensitivity only in patients who were more insulin 
Table 1 - Baseline and post-treatment characteristics of the patients
Parameter Pre-treatment diet (n = 10)
Post-treatment diet 
(n = 10)
Pre-treatment
orlistat (n = 14)
Post-treatment
orlistat (n = 14)
Age (years) 46.8 ± 5.8 47.9 ± 9.3
BMI (kg/m²) 36.0 ± 7.6 33.0 ± 7.0* 35.4 ± 5.9 32.5 ± 5.9*
Waist circumference (cm) 106.1 ± 12.7 97.7 ± 10.6* 102.0 ± 9.0 95.1 ± 11.1*
24-hour systolic BP (mm Hg) 126.5 ± 12.6 121.1 ± 12.6 139.5 ± 12.7** 132.9 ± 13.0*
24-hour diastolic BP (mm Hg) 79.8 ± 8.3 78.6 ± 10.6 88.3 ± 8.6** 86.2 ± 10.4
Visceral fat (cm) 5.5 ± 1.5 4.0 ± 1.2* 4.6 ± 1.2 3.9 ± 1.3*
Total cholesterol (mg/dL) 210.5 ± 35.5 207.9 ± 39.2 200.9 ± 33.1 180.3 ± 24.9*
HDL-cholesterol (mg/dL) 44.3 ± 14.1 47.4 ± 16.9 41.1 ± 12.2 43.6 ± 9.8
Triglycerides (mg/dL) 142.2 ± 46.2 117.9 ± 52.9* 137.5 ± 56.0 111.3 ± 42.9
LDL-cholesterol (mg/dL) 137.8 ± 31.5 136.8 ± 32.3 132.3 ± 35.4 114.0 ± 24.1
* p < 0.05 for pre- vs. post-treatment within groups; ** p < 0.05 for pre-treatment differences between  groups. n - number of patients; BMI - body mass 
index; BP - blood pressure; HDL-cholesterol - high-density lipoprotein cholesterol; LDL-cholesterol - low-density lipoprotein cholesterol.
Table 2 - Baseline and post-treatment characteristics of the patients
Parameter Pre-treatment diet (n = 10)
Post-treatment diet 
(n = 10)
Pre-treatment
orlistat (n = 14)
Post-treatment
orlistat (n = 14)
Fasting glucose (mg/dL) 92.7 ± 7.6 87.7 ± 8.8* 113.5 ± 28.1** 97.9 ± 12.2*
120-min glucose (mg/dL) 127.5 ± 23.0 114.7 ± 28.3 173.4 ± 60.8** 142.4 ± 47.1*
ISI 1.23 ± 0.23 1.23 ± 0.25 1.10 ± 0.28 1.23 ± 0.19*
HOMA-R 4.0 ± 2.4 3.9 ± 2.0 7.2 ± 4.2** 5.3 ± 2.3
Adiponectin (ng/mL) 7.4 ± 3.4 7.1 ± 3.5 6.5 ± 1.8 5.9 ± 2.1
IL-6 (pg/mL) 1.1 ± 0.3 1.1 ± 0.4 1.2 ± 0.4 1.6 ± 0.9
Leptin (ng/mL) 62.4 ± 31.9 52.1 ± 37.5 39.4 ± 27.1 31.6 ± 8.6*
CRP (ng/mL) 0.48 ± 0.45 0.44 ± 0.31 0.95 ± 0.81 0.51 ± 0.41
TNF-a (pg/ml) 18.8 ± 7.1 8.2 ± 1.2* 24.5 ± 13.4 9.7 ± 7.0*
* p < 0.05 for pre vs. post-treatment within groups; ** p < 0.05 for pre-treatment differences between groups. n - number of patients; ISI - insulin 
sensitivity index; HOMA-R - insulin resistance index (homeostasis model assessment of insulin resistance); IL-6 - interleukin-6; CRP - C-reactive protein; 
TNF-a - tumor necrosis factor-alpha.
Fig. 1 - Pre- and post-weight loss changes in serum TNF-a according to 
treatment.
diet diet + orlistat
pre-TNF-α post-TNF-α
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resistant before treatment10,11. They also agree with the results 
from the XENDOS study (XENical in the Prevention of Diabetes 
in Obese Subjects)6, in which orlistat  improved glucose 
parameters and even helped to prevent diabetes in patients 
with impaired glucose tolerance. Nevertheless, one cannot say 
that these effects were independent of the weight loss, since 
mean weight reduction in the orlistat group at the end of the 
XENDOS study was higher than in the placebo group. 
Unlike other studies that reported increased levels of 
adiponectin with weight loss, in our study no significant 
changes were found in adiponectin concentrations in both 
treatment groups12,13. On the other hand, some studies have 
shown no increase in adiponectin levels with weight loss 
either, yet insulin resistance improved, as was the case in our 
study14-16. Although at the beginning of treatment adiponectin 
was positively correlated with ISI and inversely correlated with 
body weight, the insulin sensitivity improvement found in 
the orlistat group was independent of adiponectin change. It 
has been recently found that serum adiponectin circulates in 
different molecular weight forms that may also have distinct 
biological functions17. Additionally, it has been demonstrated 
that weight reduction not only leads to changes in adiponectin 
levels, but also in the distribution of its circulating forms, with 
decreased levels of low molecular weight forms and increased 
levels of middle and high molecular weight forms, thereby 
improving insulin sensitivity17. Abbasi et al18, however, found 
no changes either in plasma adiponectin or in the distribution 
of adiponectin oligomers with weight loss, even though 
insulin sensitivity improved18. It is possible that weight loss 
may improve insulin sensitivity by mechanisms other than 
adiponectin action, such as mobilization of liver19 and muscle 
lipid content20.
IL-6 remained unchanged in both groups after weight 
loss. Our findings differ from those reported by Bastard et 
al21. These authors demonstrated that, in obese, nondiabetic 
female patients, a modest weight loss (a decrease of about 
5.0% in BMI) resulted in a significant reduction in serum IL-6 
and the expression of IL-6 in subcutaneous adipose tissue21. 
In the present study, however, patients were more obese and 
had significantly higher IL-6 levels, and these pretreatment 
differences might explain the differing results.
There was a significant decrease in TNF-a levels regardless 
of the treatment used, and changes in TNF-a were not 
correlated with changes in insulin resistance indices. Results of 
studies correlating weight loss with TNF-a are conflicting22,23. 
Samuelsson et al24 compared weight reduction with orlistat 
versus placebo and, taking into account patients from both 
groups who lost more than 10% of their baseline weight, 
concluded that TNF-a levels were lower in the orlistat than 
in the placebo group24. In the present study, in which mean 
weight loss was 8%, there was no further reduction in TNF-a 
in the orlistat-treated patients and, therefore, the changes 
observed are not attributed to this drug. In the study by 
Monzillo et al25, the decline in TNF-a levels with weight loss 
through caloric restriction and physical activity was found 
only in patients with impaired glucose tolerance, but not in 
diabetic subjects or those with normal glucose tolerance25. 
Kopp et al26 also assessed the impact gastroplasty to treat 
obesity on adipocytokine levels according to the glucose 
tolerance status26. In their study, mean body weight decreased 
by 32.3%, and no significant change was observed in TNF-
a levels in either group. The reasons for these differences 
remain unclear. The baseline characteristics of the sample, 
such as body weight, degree of insulin resistance, and time 
of follow-up, may be important to determine adipocytokine 
response to weight loss. 
Even though a tendency to decreased levels of CRP was 
seen in the orlistat-treated patients, these changes were 
not statistically significant in either group. The decrease 
in CRP levels showed no correlation with the decrease in 
body weight, but there was a positive correlation with the 
decrease in waist circumference.  Moreover, CRP levels 
were negatively correlated with the insulin sensitivity index, 
suggesting that the subclinical inflammatory activity may play 
a role in the degree of insulin resistance and, thereby, in 
impaired glucose tolerance. The relevance of this association 
between inflammation and insulin resistance is corroborated 
by evidence indicating that increased levels of inflammatory 
markers may predict the development of type-2 diabetes 
mellitus27,28. The elevated levels of CRP at baseline may 
contribute to establishing a clearer relationship between 
decreased CRP and weight reduction26, and most studies have 
shown that the degree of CRP decrease was linearly related 
to the amount of weight lost24,29. Our data suggest that de 
decrease in CRP depends more on the decrease in abdominal 
fat than on weight loss itself, as corroborated by Marfella et 
al30. In fact, patients with more centralized fat had also higher 
levels of inflammatory markers.
Conclusion
This study’s findings suggest that a weight loss greater than 
5% is associated with an improvement in inflammatory status 
and a decrease in insulin resistance, regardless of adiponectin 
increases and TNF-a reductions. Because of the differences 
in glucose tolerance between both groups studied, our data 
do not allow us to attribute the greater benefit found in the 
orlistat group to the use of this drug. 
Fig. 2 - Correlation between C-reactive protein and insulin sensitivity index (ISI).
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